NCT04400721

Brief Summary

This study aims to study the analgesic and respiratory effects of the erector spinae plane block for patients undergoing video-assisted thoracic surgery (VATS) or robotic assisted thoracic surgery (RATS).

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Jul 2020

Typical duration for phase_3

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 19, 2020

Completed
3 days until next milestone

First Posted

Study publicly available on registry

May 22, 2020

Completed
1 month until next milestone

Study Start

First participant enrolled

July 1, 2020

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 28, 2022

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2023

Completed
Last Updated

May 28, 2020

Status Verified

May 1, 2020

Enrollment Period

2 years

First QC Date

May 19, 2020

Last Update Submit

May 26, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Efficacy of ESP block in decreasing postoperative pain intensity

    Pain levels will be assessed using the 10 points Visual analogue Scale (VAS) where zero= no pain and 10= pain as bad as it can be. The vaS is a validated tool to measure pain and discomfort. It is sensitive to pharmacological and non-pharmacological interventions, that have an impact over the experience of pain, as well as it's high correlation with pain levels

    48 hours

Study Arms (3)

PCIA arm

NO INTERVENTION

Standard post-operative treatment with patient-controlled intravenous analgesia (Piritramide bolus = 2mg, bolus interval = 7 minutes, max 4 hour dose = 30mg)

ESP block arm

ACTIVE COMPARATOR

ultrasound guided Erector spinae block (Single shot of 30ml of 0.5% solution of Naropin \[Ropivacaine\])

Drug: Erector spinae plane block with ropivacaine 3.75mg/ml

IC block arm

ACTIVE COMPARATOR

3 ml of 0.5% solution of Naropin \[Ropivacaine\] per intercostal space, up to a maximum of 30ml

Drug: Erector spinae plane block with ropivacaine 3.75mg/ml

Interventions

Single shot erector spinae block

Also known as: Naropin
ESP block armIC block arm

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male and female patients
  • age between 18 to 100 years old
  • ASA 1-3
  • scheduled for VATS
  • informed consent explained and signed

You may not qualify if:

  • Patients \< 18 years old, \> 100 years old
  • ASA physical status \> 3
  • previous cardiac surgery or ipsilateral thoracic surgery
  • neuropsychiatric diseases
  • allergy to analgesics or local anesthetics or other medications used in the study
  • abuse of opioids or sedatives
  • contraindication to receive regional anesthesia (e.g. coagulation defect)
  • patients who could not understand the VAS pain-scoring system
  • patient refusal to follow participation
  • expected post operative mechanical ventilation
  • intolerance or allergy to any prescribed medication

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Pain, PostoperativePostoperative Complications

Interventions

Ropivacaine

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Central Study Contacts

Domien Vanhonacker, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: Single-blinded, single-center, randomized, prospective study
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 19, 2020

First Posted

May 22, 2020

Study Start

July 1, 2020

Primary Completion

June 28, 2022

Study Completion

February 1, 2023

Last Updated

May 28, 2020

Record last verified: 2020-05

Data Sharing

IPD Sharing
Will not share